Type 1 and type 2 diabetes mellitus: Are they mutually exclusive?

Singapore Medical Journal

Volumn 54, Issue 7, 2013, Pages 396-400

  Fatima, Aziz ^a   Khawaja, Khadija Irfan ^a   Burney, Saira ^a   Minhas, Khushroo ^a   Mumtaz, Usman ^a   Masud, Faisal ^a  

^a SERVICES HOSPITAL   (Pakistan)

Author keywords

Autoantibodies; Insulin resistance; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

AUTOANTIBODY; BIOCHEMICAL MARKER; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; INSULIN; REPAGLINIDE;

ACANTHOSIS NIGRICANS; ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN RESISTANCE; MALE;

EID: 84880604286     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: 10.11622/smedj.2013141     Document Type: Article

References (29)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 Suppl 1:64-71.
2. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
3. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57:158-161.
4. Tsui H, Paltser G, Chan Y, Dorfman R, Dosch HM. 'Sensing' the link between type 1 and type 2 diabetes. Diabetes Metab Res Rev 2011; 27:913-918.
5. Nadeau KJ, Regensteiner JG, Bauer TA et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 2010; 95:513-521.
6. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167:40-46.
7. Negishi M, Shimomura K, Proks P, et al. An obese patient with slowly progressive type 1 diabetes diagnosed by ketoacidosis. Intern Med 2010; 49:393-395.
8. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1:111-115.
9. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 2006.
10. Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-1 and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35:768-773.
11. Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798-1811.
12. LaFontaine T. Physical Activity: The Epidemic of Obesity and Overweight Among Youth: Trends, Consequences, and Interventions. American Journal of Lifestyle Medicine 2008; 2:30-36.
13. Suzuki T, Takahashi K, Miyamoto S, et al. "Type 1 on type 2" diabetes mellitus: autoimmune type 1 diabetes superimposed on established type 2 diabetes. Intern Med 2007; 46:1957-1962.
14. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1487-1495.
15. Szadkowska A, Pietrzak I, Bodalska-Lipińska J, et al. [Insulin resistance in young type 1 diabetic patients]. Diabetologia Doświadczalna i Kliniczna 2006; 6:293-298. Polish.
16. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007; 30:2314-2320.
17. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care 2011; 34 Suppl 2:166-170.
18. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes. J Autoimmun 1996; 9:379-383.
19. Winter WE, Harris N, Schatz D. Immunologic markers in the diagnosis and prediction of autoimmune, type 1A diabetes. Clinical Diabetes 2002; 20:183-191.
20. Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005; 19:119-133.
21. Zimmet PZ, Tuomi T, Mackay IR. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11:299-303.
22. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 4:703-8.
23. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57:168-75.
24. Juneja R, Hirsch IB, Naik RG, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50:1008-13.
25. Turner R, Stratton I, Horton V, et al. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes (UKPDS 25). Lancet 1997; 350:1288-1293.
26. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51:1754-1762.
27. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86:3032-3038.
28. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45:622-626.
29. Anastasi E, Dotta F, Tiberti C, et al. Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. Autoimmunity 1995; 29:249-256.